We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Fecal Pharmacokinetics and Gut Microbiome Effects of Oral Omadacycline Versus Vancomycin in Healthy Volunteers.
- Authors
Jo, Jinhee; Hu, Chenlin; Begum, Khurshida; Wang, Weiqun; Le, Thanh M; Agyapong, Samantha; Hanson, Blake M; Ayele, Hossaena; Lancaster, Chris; Alam, M Jahangir; Gonzales-Luna, Anne J; Garey, Kevin W
- Abstract
Background Clostridioides difficile infection (CDI) is a common healthcare-associated infection with limited treatment options. Omadacycline, an aminomethylcycline tetracycline, has potent in vitro activity against C difficile and a low propensity to cause CDI in clinical trials. We aimed to assess fecal pharmacokinetics and gut microbiome effects of oral omadacycline compared to oral vancomycin in healthy adults. Methods This was a phase 1, nonblinded, randomized clinical trial conducted in healthy volunteers aged 18–40 years. Subjects received a 10-day course of omadacycline or vancomycin. Stool samples were collected at baseline, daily during therapy, and at follow-up visits. Omadacycline and vancomycin stool concentrations were assessed, and microbiome changes were compared. Results Sixteen healthy volunteers with a mean age of 26 (standard deviation [SD], 5) years were enrolled; 62.5% were male, and participants' mean body mass index was 23.5 (SD, 4.0) kg/m2. Omadacycline was well tolerated with no safety signal differences between the 2 antibiotics. A rapid initial increase in fecal concentrations of omadacycline was observed compared to vancomycin, with maximum concentrations achieved within 48 hours. A significant difference in alpha diversity was observed following therapy in both the omadacycline and vancomycin groups (P <.05). Bacterial abundance and beta diversity analysis showed differing microbiome changes in subjects who received omadacycline versus vancomycin. Conclusions Subjects given omadacycline had high fecal concentrations with a distinct microbiome profile compared to vancomycin. Clinical Trials Registration NCT06030219.
- Subjects
GUT microbiome; CLINICAL trial registries; VANCOMYCIN; CLOSTRIDIUM diseases; CLOSTRIDIOIDES difficile; PHARMACOKINETICS
- Publication
Journal of Infectious Diseases, 2024, Vol 229, Issue 1, p273
- ISSN
0022-1899
- Publication type
Article
- DOI
10.1093/infdis/jiad537